Ani Pharmaceuticals (ANIP) Capital Expenditures (2010 - 2026)

Ani Pharmaceuticals has disclosed Capital Expenditures across 17 years of filings, most recently posting $3.1 million for Q2 2026.

• In Q2 2026, Capital Expenditures fell 23.92% year-over-year to $3.1 million; the TTM figure through Jun 2026 stood at $16.5 million (up 20.31% YoY), while the FY2025 annual figure was $13.8 million, down 14.79% from the prior year.
• Capital Expenditures came in at $3.1 million for Q2 2026 at Ani Pharmaceuticals, down from $6.1 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $6.1 million in Q3 2025 to a low of $1.2 million in Q4 2025.
• Average Capital Expenditures over 5 years is $3.2 million, with a median of $2.5 million recorded in 2023.
• Year-over-year, Capital Expenditures jumped 781.46% in 2022 and sank 48.04% in 2025.
• Over 5 years, Capital Expenditures stood at $3.1 million in 2022, then slipped by 27.37% to $2.3 million in 2023, then gained by 5.05% to $2.4 million in 2024, then slumped by 48.04% to $1.2 million in 2025, then surged by 145.5% to $3.1 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $3.1 million in Q2 2026, $6.1 million in Q1 2026, and $1.2 million in Q4 2025.